Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 5/20 | 0.45 |
| ▸ | EGFR | P00533 | 9/20 | 0.44 |
| ▸ | BRAF | P15056 | 4/20 | 0.43 |
| ▸ | TNNI3K | Q59H18 | 4/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | ABL2 | P42684 | 1/20 | 0.43 |
| ▸ | TTBK1 | Q5TCY1 | 2/20 | 0.42 |
| ▸ | TTBK2 | Q6IQ55 | 2/20 | 0.42 |
| ▸ | FADS1 | O60427 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4771837 | 1.00 | CSF1R (0.45) | CSF1REGFRBRAFTNNI3KABL1 | |
| SCHEMBL4764864 | 0.92 | CSF1R (0.46) | CSF1REGFRBRAFTNNI3KABL1 | |
| SCHEMBL4764871 | 0.92 | CSF1R (0.46) | CSF1REGFRBRAFTNNI3KABL1 | |
| SCHEMBL4769546 | 0.82 | BRAF (0.46) | EGFRBRAFTNNI3KABL1ABL2 | |
| SCHEMBL4769551 | 0.82 | BRAF (0.46) | EGFRBRAFTNNI3KABL1ABL2 | |
| SCHEMBL4764777 | 0.81 | BRAF (0.47) | EGFRBRAFTNNI3KABL1ABL2 | |
| SCHEMBL4764781 | 0.81 | BRAF (0.47) | EGFRBRAFTNNI3KABL1ABL2 | |
| SCHEMBL4764393 | 0.78 | BRAF (0.45) | EGFRBRAFTNNI3KABL1ABL2 | |
| SCHEMBL4764386 | 0.78 | BRAF (0.45) | EGFRBRAFTNNI3KABL1ABL2 | |
| SCHEMBL2461054 | 0.78 | BRAF (0.64) | EGFRBRAFTNNI3KABL1ABL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0938486-B1 | SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 2008-01-16 | — | — | EP | claimed |
| US-6180636-B1 | USED TO INHIBIT THE TYROSINE KINASE ACTIVITY OF THE RECEPTOR FOR THE EPIDERMAL GROWTH FACTOR AND C-ERBB2 KINASE AND CAN BE USED AS ANTITUMOR AGENTS | NOVARTIS AG (CH) | 2001-01-30 | — | — | US | claimed |
| EP-0938486-A1 | SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION | Novartis AG (CH) | 1999-09-01 | — | — | EP | claimed |
| WO-1998007726-A1 | SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 1998-02-26 | — | — | WO | claimed |
| EP-0938486-B1 | SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 2008-01-16 | — | — | EP | disclosed |
| US-6180636-B1 | USED TO INHIBIT THE TYROSINE KINASE ACTIVITY OF THE RECEPTOR FOR THE EPIDERMAL GROWTH FACTOR AND C-ERBB2 KINASE AND CAN BE USED AS ANTITUMOR AGENTS | NOVARTIS AG (CH) | 2001-01-30 | — | — | US | disclosed |
| EP-0938486-A1 | SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION | Novartis AG (CH) | 1999-09-01 | — | — | EP | disclosed |
| WO-1998007726-A1 | SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 1998-02-26 | — | — | WO | disclosed |